Pancreatic Pharmaceuticals

Pancreatic Pharmaceuticals is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Pancreatic Pharmaceuticals. Pancreatic Pharmaceuticals is spin off company of Micar Innovation, registered in Sofia, Bulgaria. Under terms of the agreement, Micar Innovation grants Pancreatic Pharmaceuticals (Sofia - Bulgaria) an exclusive option to license and develop MIC6479 drugs targeting Pancreatic Cancer disease. Pancreatic Pharmaceuticals capital is in the hands of Micar Innovation driven by impact and provide value to our future investors. AIM Pancreatic Pharmaceuticals (spin off company of Micar Innovation) is specialized in the discovery, development and commercialization of the small molecule drugs and transforming the treatment of Pancreatic cancer by advancing one of the largest, exclusively cancer-focused clinical pipelines of novel therapies. By using structure based in silico drug design & AI (Micar21 platform) we constructed the best Pancreatic Cancer drug candidate fast & validated. We aim to bridge the safety and efficacy gaps in current approaches to Pancreatic Cancer management. Pancreatic Pharmaceuticals lead drug candidate, MIC6479, is currently in the phase preclinical for the treatment of Pancreatic Cancer.